CytomX Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CytomX Therapeutics, Inc. (CTMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 779.90 thousand shares for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2017-11-07
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-09-30 was 208.58K shares, a 1279.03% increase year-over-year.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-06-30 was 349.77K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-03-31 was 221.55K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2016-09-30 was 15.13K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month |
|---|---|---|---|
| 2017-09-30 | 208.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 558.35K shares derived: sum of 2 quarters · filed 2017-11-07 | 779.90K shares 10-Q · filed 2017-11-07 |
| 2017-06-30 | 349.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 571.32K shares 10-Q · filed 2017-08-07 | |
| 2017-03-31 | 221.55K shares 10-Q · filed 2017-05-05 | ||
| 2016-09-30 | 15.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 54.16K shares 10-Q · filed 2016-11-03 | |
| 2016-06-30 | 39.03K shares 10-Q · filed 2016-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |